The antibody response of haematological malignancies to COVID-19 infection and vaccination

Letter Oncology

Care without a compass: Including patients with cancer in COVID-19 studies

Christopher R. Friese et al.

CANCER CELL (2021)

添加到收藏夹

Article Medicine, General & Internal

Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data

Robert H Shaw et al.

LANCET (2021)

添加到收藏夹

Editorial Material Oncology

Short-term safety of the BNT162b2 mRNA COVID-19 vaccine in patients with cancer treated with immune checkpoint inhibitors

Barliz Waissengrin et al.

LANCET ONCOLOGY (2021)

添加到收藏夹

Article Oncology

COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trials

Aakash Desai et al.

Summary: The rapid development of COVID-19 vaccines has provided new hope of mitigating the disease, and it is necessary to prioritize cancer patients, including those participating in oncology clinical trials, for vaccination. Data on the safety, tolerability and efficacy of the vaccines in patients with cancer are currently limited, but the benefits of vaccination are likely to far outweigh the risks of adverse events.

NATURE REVIEWS CLINICAL ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Seroconversion rates following COVID-19 vaccination among patients with cancer

Astha Thakkar et al.

Summary: Most cancer patients show high seroconversion rates after receiving COVID-19 vaccines, but those with hematologic malignancies, especially after highly immunosuppressive therapies, exhibit lower conversion rates. Patients on immune checkpoint inhibitor therapy or hormonal therapy display high conversion rates.

CANCER CELL (2021)

添加到收藏夹

Editorial Material Biochemistry & Molecular Biology

A correlate of protection for SARS-CoV-2 vaccines is urgently needed

Florian Krammer

NATURE MEDICINE (2021)

添加到收藏夹

Article Oncology

Production and persistence of specific antibodies in COVID-19 patients with hematologic malignancies: role of rituximab

C. Cattaneo et al.

Summary: This study found that the ability of patients with hematologic malignancies to develop an effective humoral immune response after COVID-19 is uncertain, with lymphoma patients having lower antibody levels and seroconversion rates compared to other hematologic malignancies, primarily due to patients who had received rituximab within 6 months before COVID-19 failing to produce sufficient antibodies.

BLOOD CANCER JOURNAL (2021)

添加到收藏夹

Letter Oncology